Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX)

Price 0.047p on 22-11-2024 at 17:30:01
Change -0.0005p -1.05%
Buy 0.05p
Sell 0.044p
Buy / Sell NFX Shares
Last Trade: Buy 129,287.00 at 0.048p
Day's Volume: 6,031,551
Last Close: 0.047p
Open: 0.0475p
ISIN: GB00BYW79Y38
Day's Range 0.00p - 0.00p
52wk Range: 0.04p - 0.44p
Market Capitalisation: £674k
VWAP: 0.047653p
Shares in Issue: 1,419m

Recent Trades History Nuformix (NFX)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 129,287 0.048p Ordinary
14:38:58 - 22-Nov-24
Sell* 100,307 0.044p Ordinary
14:31:56 - 22-Nov-24
Buy* 266,847 0.048p Ordinary
14:31:28 - 22-Nov-24
Buy* 540,598 0.04832p Ordinary
14:29:08 - 22-Nov-24
Sell* 1,000,000 0.0459p Ordinary
14:19:01 - 22-Nov-24
Buy* 200,000 0.0488p Ordinary
14:15:13 - 22-Nov-24
Sell* 2,690,747 0.0477p Ordinary
13:45:51 - 22-Nov-24
Sell* 1,103,765 0.0488p Ordinary
08:07:34 - 22-Nov-24

Share Price History for Nuformix

Time period:
to
Date Open High Low Close Volume

Share News for Nuformix

UK shareholder meetings calendar - next 7 days

28th Oct 2024 12:27

Read More

IN BRIEF: Nuformix shares fall despite interim loss narrowing

18th Jun 2024 18:37

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss narrows to GBP242,529 from GBP337,622. Read More

Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment

17th Jun 2024 10:37

(Alliance News) - Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Read More

UK shareholder meetings calendar - next 7 days

12th Mar 2024 14:30

Read More

IN BRIEF: Nuformix announces subscription to raise GBP150,000

1st Mar 2024 10:31

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More

FTSE 100 Latest
Value8,262.08
Change112.81

Login to your account

Forgot Password?

Not Registered